Support for Expanding MOUD
DEA supports collaboration amongst all DEA registrants to ensure there is an adequate and uninterrupted supply of MOUD products when appropriately prescribed. Distributors should carefully examine any quantitative thresholds they have established to ensure that individuals with opioid use disorder (OUD) who need buprenorphine are able to access it without undue delay.
An Addiction Psychiatrist’s Encounter with a DEA Scammer
Increased overdoses, many attributed to an influx of synthetic fentanyl, has put a spotlight on those who care for patients with opioid use disorders. Hundreds of prescribers are being targeted in an elaborate scam by imposters posing as DEA agents in an attempt to extort money. Over a series of phone calls, the imposters put their marks at ease, seeming to be on their side. By the time the imposters ask for money, many are willing to pay—just to make the issue go away. Scammers use the names of real DEA agents and alter their voices with artificial intelligence to make them sound as if they have regional accents that are convincing. The scammers are set up overseas.
MATE Act Training Requirements (Video)
As Congressionally-mandated, medical practitioners have a new role to help patients fighting to sustain recovery and prevent opioid overdoses. All medical registrants submitting a new or renewing a current registration must attest to completing an eight-hour training to treat patients overcoming opioid and other substance use disorders.
Learn About SAMHSA’s Behavioral Health Equity Challenge
We wanted to share this message from SAMHSA about its Behavioral Health Equity Challenge.
SAMHSA Recommendations for Curricular Elements in Substance Use Disorders Training
SAMHSA provides information on how practitioners can meet the requirement.
Requirements for Training as Part of the MATE Act
PCSS wanted to share this email from the federal Drug Enforcement Agency regarding new training requirements.
Removal of DATA Waiver (X-Waiver) Requirement
Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications).
CDC’s Draft Clinical Practice Guideline for Prescribing Opioids Now Open for Public Comment
CDC’s draft updated Clinical Practice Guideline for Prescribing Opioids is open for public comment now through April 11, 2022. Please add your feedback on this important update: https://go.usa.gov/xtAW5
American Medical Association Releases Overdose Toolkit
The American Medical Association has released a toolkits that recommends states expand treatment of opioid use disorder in Medicaid and commercial insurance and remove barriers, such as prior authorization and other utilization management policies. Additionally, treatment must address disparities and the needs of all patients equitably, including vulnerable populations. The toolkit also highlights the importance […]
Thank you for your patience while we make improvements
PCSS is in the midst of updating its learner management system with the goal of making your life easier. While we do this, we’re encountering a few bumps in the road. Ultimately, we hope your learning experience is more seamless while we continue to offer webinars, clinical round tables, and all the other trainings you’ve […]
